<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373123</url>
  </required_header>
  <id_info>
    <org_study_id>CHESS1703</org_study_id>
    <nct_id>NCT03373123</nct_id>
  </id_info>
  <brief_title>Radiomics-based Surrogate of Endoscopy (rEndosc) (CHESS1703)</brief_title>
  <acronym>rEndosc</acronym>
  <official_title>Radiomics-based Surrogate of Endoscopy (rEndosc) for Noninvasive Prediction of Esophageal Varices and Risk Stratification of Variceal Hemorrhage in Hepatitis B Virus-related Cirrhosis (CHESS1703)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>302 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xingtai People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal varices (EVs) resulting from portal hypertension are a prevalent complication of
      cirrhosis with a high mortality when variceal hemorrhage (VH) occurs. Screening endoscopy for
      EVs is recommended for all patients with cirrhosis, and prophylactic treatments are proposed
      for preventing VH, which may be financially onerous. Therefore, noninvasive tools for
      diagnosing EVs and risk stratifying VH in cirrhotic patients are needed to decrease the
      number of unnecessary invasive endoscopic examinations of low-risk patients and avoid
      unneeded prophylactic treatment. This is a prospective, multi-center diagnostic trial
      conducted at 9 high-volume liver centers in China designed to determine the diagnostic
      performance of radiomics-based surrogate (rEndosc) (investigational technology) by CT imaging
      for noninvasive prediction of EVs and risk stratification of VH in patients with hepatitis B
      virus-related cirrhosis using endoscopic examinations as reference standard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esophageal varices (EVs) resulting from portal hypertension are a prevalent complication of
      cirrhosis with a high mortality when variceal hemorrhage (VH) occurs. Screening endoscopy for
      EVs is recommended for all patients with cirrhosis, and prophylactic treatments are proposed
      for preventing VH, which may be financially onerous. Therefore, noninvasive tools for
      diagnosing EVs and risk stratifying VH in cirrhotic patients are needed to decrease the
      number of unnecessary invasive endoscopic examinations of low-risk patients and avoid
      unneeded prophylactic treatment. This is a prospective, multi-center diagnostic trial
      conducted at 9 high-volume liver centers (Beijing YouAn Hospital, Capital Medical University;
      Nanfang Hospital, Southern Medical University; 302 Hospital of PLA; Shandong Provincial
      Hospital; Beijing Friendship Hospital, Capital Medical University; Chinese PLA General
      Hospital; Peking University People's Hospital; Xingtai People's Hospital) in China designed
      to determine the diagnostic performance of radiomics-based surrogate (rEndosc)
      (investigational technology) by CT imaging for noninvasive prediction of EVs and risk
      stratification of VH in patients with hepatitis B virus-related cirrhosis using endoscopic
      examinations as reference standard.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">December 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Accuracy of rEndosc for Esophageal Varices</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic accuracy of rEndosc to determine the presence or absence of esophageal varices when compared to endoscopic examination as the reference standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Accuracy of rEndosc for the Risk of Variceal Hemorrhage</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic accuracy of rEndosc to stratify risk of variceal hemorrhage when compared to endoscopic examination as the reference standard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Accuracy of rEndosc for Variceal Hemorrhage</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic accuracy of rEndosc to determine the presence or absence of variceal hemorrhage within 1-year follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Esophageal Varices in Cirrhosis of the Liver</condition>
  <arm_group>
    <arm_group_label>Single arm study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy</intervention_name>
    <description>Endoscopy</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CTA</intervention_name>
    <description>Radiomic features were extracted from CTA images.</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years;

          -  HBsAg positive;

          -  confirmed cirrhosis based on results of histologic examination of liver tissue or
             combined physical, laboratory, and radiologic findings, including a nodular surface, a
             coarse texture, and an enlarged caudate lobe of the liver on ultrasonography, CT, or
             MR imaging.

        Exclusion Criteria:

          -  active alcohol abuse (less than 6 months of alcohol abstinence); portal thrombosis;

          -  history of treatments for portal hypertension (drug therapy, such as Î²-blocker,
             vasopressin) within 2 weeks;

          -  prior surgeries (such as splenectomy, partial splenic embolization/devascularization,
             transjugular intrahepatic portosystemic shunt);

          -  prior endoscopic therapies (such as endoscopic variceal ligation);

          -  previous variceal hemorrhage;

          -  acute-on-chronic (sub-acute) liver failure;

          -  malignant tumor (such as hepatocellular carcinoma);

          -  cirrhotic portal hypertension with isolated gastric varices or ectopic varices;

          -  inability to adhere to study procedures (such as heart failure, renal failure);

          -  pregnancy or unknown pregnancy status;

          -  no informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiguo Ding, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing YouAn Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolong Qi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huiguo Ding, M.D.</last_name>
    <phone>86-13911683832</phone>
    <email>huiguoding@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>302 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongping Yang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yongping Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanwei Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shutian Zhang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shutian Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liqin Zhao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiguo Ding, MD</last_name>
      <email>dinghuiguo@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Huiguo Ding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peng Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yingdi Liu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yingdi Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yulan Liu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yulan Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhechuan Mei, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhechuan Mei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaolong Qi, MD</last_name>
      <email>qixiaolong@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaolong Qi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinjun Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dengxiang Liu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dengxiang Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Changzeng Zuo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunqing Zhang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chunqing Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1. Erratum in: Hepatology. 2017 Jul;66(1):304.</citation>
    <PMID>27786365</PMID>
  </reference>
  <reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </reference>
  <reference>
    <citation>Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016 Feb;278(2):563-77. doi: 10.1148/radiol.2015151169. Epub 2015 Nov 18.</citation>
    <PMID>26579733</PMID>
  </reference>
  <reference>
    <citation>Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, Chan BK, Matcuk GR, Barry CT, Chang HY, Kuo MD. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol. 2007 Jun;25(6):675-80. Epub 2007 May 21.</citation>
    <PMID>17515910</PMID>
  </reference>
  <reference>
    <citation>Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017 Dec;14(12):749-762. doi: 10.1038/nrclinonc.2017.141. Epub 2017 Oct 4. Review.</citation>
    <PMID>28975929</PMID>
  </reference>
  <reference>
    <citation>Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, Ma ZL, Liu ZY. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. J Clin Oncol. 2016 Jun 20;34(18):2157-64. doi: 10.1200/JCO.2015.65.9128. Epub 2016 May 2. Erratum in: J Clin Oncol. 2016 Jul 10;34(20):2436.</citation>
    <PMID>27138577</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Director, Portal Hypertension Research, Institute of Hepatology</investigator_title>
  </responsible_party>
  <keyword>Esophageal Varices</keyword>
  <keyword>Variceal Hemorrhage</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Radiomics</keyword>
  <keyword>Hepatitis B Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

